Lantheus (NasdaqGM:LNTH) FY Conference Transcript

Summary of Lantheus Conference Call Company Overview - Company: Lantheus - Key Executives: Mary Anne Heino (CEO), Bob Marshall (CFO) - Event: TD Cowen's 46th Annual Healthcare Conference Core Industry Insights - Focus on Diagnostics: Lantheus has strategically chosen to focus on its diagnostic assets over therapeutic assets, citing a broad portfolio that was too extensive for the company's current scale and capitalization [3][4] - Recent Acquisitions: The company completed significant M&A activities in 2025, acquiring LMI and Evergreen, which contributed to the expanded portfolio [4] Key Product Developments - PYLARIFY Launch: The new formulation of PYLARIFY is set to launch, with key milestones including obtaining coding, coverage, and reimbursement. The company aims for pass-through status by October 1, 2026, and HCPCS code submission by April 1, 2026 [6][9][12] - Increased Production Capacity: The new formulation is expected to yield up to 50% more doses per batch compared to the current formulation, enhancing market availability [14][15] - PNT2003 Asset: Lantheus received conditional FDA approval for PNT2003, which is positioned as a radio equivalent to Lutathera. The company is preparing for commercialization, pending the expiration of the Hatch-Waxman litigation period [5][38][39] Financial Guidance - Revenue Projections: For 2026, Lantheus provided revenue guidance of $1.4 billion to $1.45 billion, adjusted for a $111 million divestiture of the SPECT business. The guidance reflects a year-over-year comparison [18][19] - EPS Guidance: The company anticipates an EPS of approximately $575 million, with investments in sales and marketing expected to be around 12%-12.5% of revenue [55] Market Dynamics - Competitive Landscape: Lantheus is aware of competitors like Telix and their new formulations. The company is monitoring pricing strategies and market dynamics closely [21] - Alzheimer's Imaging Market: Lantheus is developing multiple products for Alzheimer's, including NeuroSeq and MK-6240, with a focus on both beta-amyloid and tau imaging. The market is seen as large and underserved, with potential for significant growth [25][27][28] Strategic Decisions - Shift from Therapeutics: The decision to focus on diagnostics over therapeutics is based on lower development costs and higher success probabilities in radiopharmaceuticals. The company aims to leverage its expertise in this area [40][42][43] - OCTEVY Rollout: The acquisition of OCTEVY is seen as complementary to Lantheus's existing portfolio, targeting near-term revenue opportunities [49] Underappreciated Aspects - Market Education: The CEO emphasized the importance of educating investors about radiopharmaceuticals and believes the stock is undervalued due to a lack of understanding in the market [60][61] This summary encapsulates the key points discussed during the conference call, highlighting Lantheus's strategic focus, product developments, financial guidance, and market dynamics.